ClinicalTrials.gov record
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
ClinicalTrials.gov ID: NCT03878524
Public ClinicalTrials.gov record NCT03878524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
ClinicalTrials.gov public records Last synced May 20, 2026, 11:51 PM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Study identification
- NCT ID
- NCT03878524
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Enrollment
- 2 participants
Conditions and interventions
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Anatomic Stage IV Breast Cancer AJCC v8
- Anemia
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Castration-Resistant Prostate Carcinoma
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphoid System Neoplasm
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Breast Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Primary Myelofibrosis
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Hematologic Malignancy
- Recurrent Hodgkin Lymphoma
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myeloproliferative Neoplasm
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Hematologic Malignancy
- Refractory Hodgkin Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Myelodysplastic Syndrome
- Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Refractory Plasma Cell Myeloma
- Refractory Primary Myelofibrosis
- Refractory Small Lymphocytic Lymphoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Unresectable Pancreatic Adenocarcinoma
Interventions
- Abemaciclib Drug
- Abiraterone Drug
- Afatinib Drug
- Bevacizumab Biological
- Bicalutamide Drug
- Biospecimen Collection Procedure
- Bortezomib Drug
- Cabazitaxel Drug
- Cabozantinib Drug
- Capecitabine Drug
- Carboplatin Drug
- Celecoxib Drug
- Cobimetinib Drug
- Copanlisib Drug
- Dabrafenib Drug
- Dacomitinib Drug
- Darolutamide Drug
- Dasatinib Drug
- Doxorubicin Drug
- Durvalumab Biological
- Enasidenib Drug
- Entrectinib Drug
- Enzalutamide Drug
- Erlotinib Drug
- Everolimus Drug
- Fluorouracil Drug
- Idelalisib Drug
- Imatinib Drug
- Ipilimumab Biological
- Lenvatinib Drug
- Leucovorin Drug
- Lorlatinib Drug
- Losartan Drug
- Nab-paclitaxel Drug
- Neratinib Drug
- Nivolumab Biological
- Olaparib Drug
- Oxaliplatin Drug
- Palbociclib Drug
- Panobinostat Drug
- Pembrolizumab Biological
- Pertuzumab Biological
- Ponatinib Drug
- Quality-of-Life Assessment Other
- Regorafenib Drug
- Ruxolitinib Drug
- Sirolimus Drug
- Sorafenib Drug
- Sunitinib Drug
- Trametinib Drug
- Trastuzumab Emtansine Biological
- Tretinoin Drug
- Vemurafenib Drug
- Venetoclax Drug
- Vismodegib Drug
- Vorinostat Drug
Drug · Biological · Procedure + 1 more
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2020
- Primary completion
- Dec 9, 2020
- Completion
- Dec 9, 2020
- Last update posted
- Mar 3, 2024
2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03878524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03878524 live on ClinicalTrials.gov.